article thumbnail

Drug safety update says fluoroquinolone antibiotics should be last resort

Hospital Pharmacy Europe

This is a strengthening of previous regulations from August 2023 , which said that fluoroquinolones should not be prescribed for mild-to-moderate or self-limiting infections, or non-bacterial conditions. The updated drug safety update followed a review into the risk of long-lasting or disabling reactions to fluoroquinolone antibiotics.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2023 is set to usher in a new era of genomics, and here are five areas where we should see significant advances. Moreover, research has shown that genetic testing can reduce adverse reactions to drugs by nearly one third. The post A new dawn of the genomic age: five areas set to be transformed in 2023 appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Innovative biologic for myasthenia gravis granted European approval

European Pharmaceutical Review

New European approval for generalised myasthenia gravis treatment EC approval of rozanolixizumab is supported by data from the Phase III MycarinG study , published in The Lancet Neurology in May 2023, according to UCB. Healthcare professionals are asked to report any suspected adverse reactions.

article thumbnail

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023

PharmaShots

with no new safety signals, the discontinuation rate due to adverse reactions (6% vs 4%) Ref: Gilead | Image: Gilead Related News:- Gilead and Arcus Present P-II Study (ARC-7) Results of Domvanalimab as 1L Treatment of Non-Small Cell Lung Cancer at ASCO 2023 PharmaShots! vs 11.2mos.), PFS rates at 6/12/18mos. vs 29.4%)/ (21.7%

article thumbnail

First-in-class phosphate absorption inhibitor approved by FDA

European Pharmaceutical Review

However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. XPHOZAH is expected to be available to eligible patients in the US in November 2023. Overall, the data showed that XPHOZAH significantly reduced elevated serum phosphorus in patients receiving maintenance hemodialysis.

FDA 112
article thumbnail

Xdemvy side effects and how to avoid them

The Checkup by Singlecare

Food and Drug Administration (FDA) in July of 2023 to treat Demodex blepharitis (inflammation of the eyelids). Adverse reactions As a new medication, most side effects of Xdemvy were observed in clinical trials under widely varying conditions. Xdemvy is an ectoparasiticide ( anti-parasitic ) eyedrop that was approved by the U.S.

article thumbnail

MHRA set to launch biobank pilot to better understand genetics and medicines safety

Hospital Pharmacy Europe

A genetic ‘biobank’ will be launched on 1 June 2023 by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to understand how a patient’s genetic make up can impact the safety of their medicines.